Tripartite Motif Containing 3 inhibits the aggressive behaviors of papillary thyroid carcinoma and indicates lower recurrence risk

2021 ◽  
Author(s):  
Yubao Song ◽  
Zefeng Gao ◽  
Zhifeng Yan ◽  
Caihong Zheng
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Recurrence Risk ◽  
Papillary Thyroid ◽  
Aggressive Behaviors ◽  
Tripartite Motif

scholarly journals The ratio of BRAFV600E alleles can be used to assess the biological behavior of papillary thyroid carcinoma

2020 ◽  
Author(s):  
Dingcun Luo ◽  
Yeqin Ni ◽  
Shirong Zhang ◽  
Yanping Xun ◽  
Pan Zhao ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Tumor Recurrence ◽  
Recurrence Risk ◽  
Tumor Stage ◽  
Biological Behavior ◽  
Clinicopathological Parameters ◽  
Quantitative Detection ◽  
Papillary Thyroid ◽  
Brafv600e Mutation

ABSTRACTBackgroundThe BRAFV600E mutations is an important molecular event in the occurrence and development of papillary thyroid carcinoma (PTC). A qualitative detection of the BRAFV600E mutation is still insufficient to explain the biological behavior of PTC. Though quantitative detection of the BRAFV600E mutation can reflect certain characteristics of PTC, its clinical value is still controversial. We aimed to investigate the association between the ratio of BRAFV600E alleles and clinicopathological parameters in PTC patients.MethodsGenomic DNA was extracted from specimens obtained from 329 PTC patients undergoing thyroidectomy. The ratio of BRAFV600E alleles was determined by amplification refractory mutation system (ARMS) and droplet digital polymerase chain reaction (ddPCR). Inconsistent results were further verified by next-generation sequencing (NGS). The clinicopathologic features, clinical tumor stage, and tumor recurrence risk stratification of all patients were correlated with the ratio of BRAFV600E alleles.ResultsThe sensitivity of ddPCR was superior to that of ARMS and almost the same as that of NGS. In total, 275 of 329 patients had the BRAFV600E mutation as determined by ARMS, ddPCR and NGS. The ratio of BRAFV600E alleles ranged from 0.17%-48.0%, with a median ratio of 12.58%, and significantly correlated with tumor size (p<0.001), capsule or extrathyroidal invasion (p<0.001), the number or rate of lymph node metastases (p<0.001), tumor stage (p=0.006) and tumor recurrence risk (p<0.001) but not with sex, age or multifocality. The ratio of BRAFV600E alleles was much lower in PTC patients with Hashimoto’s thyroiditis than in those without (p<0.001).ConclusionsThe ratio of BRAFV600E alleles can reliably reflect the biological behavior of PTC, making it a molecular-based stratification index of recurrence risk. The quantitative detection of BRAFV600E has the potential to guide the clinical diagnosis and treatment of PTC.

Tripartite motif containing 14: An oncogene in papillary thyroid carcinoma

2020 ◽  
Vol 521 (2) ◽  
pp. 360-367
Author(s):  
Wenyu Sun ◽  
Yunjun Wang ◽  
Duanshu Li ◽  
Yi Wu ◽  
Qinghai Ji ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Tripartite Motif

Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk

2016 ◽  
Vol 41 (8) ◽  
pp. 606-613 ◽  
Author(s):  
Aamna Hassan ◽  
Mairah Razi ◽  
Saima Riaz ◽  
Madeeha Khalid ◽  
M. Khalid Nawaz ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Recurrence Risk ◽  
Papillary Thyroid

scholarly journals USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma

2018 ◽  
Vol 45 (5) ◽  
pp. 2044-2053 ◽  
Author(s):  
Meng Jia ◽  
Yaman Guo ◽  
Xiubo Lu
Keyword(s):  
Cell Cycle ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Multivariate Analyses ◽  
Disease Free Survival ◽  
Recurrence Risk ◽  
Disease Recurrence ◽  
Migration And Invasion ◽  
Papillary Thyroid ◽  
Normal Thyroid

Background/Aims: To investigate the clinical significance and functional mechanisms of deubiquitinase USP33 in papillary thyroid carcinoma (PTC). Methods: Immunohistochemistry staining was conducted to explore the expression of USP33 in PTC tissues and adjacent normal thyroid tissues. Patients’ prognosis was evaluated by disease-free survival. The prognostic role of USP33 was tested by univariate and multivariate analyses. To confirm the effect of USP33 in cell proliferation and invasion, overexpression and knockdown of USP33 were performed in two PTC cell lines. Besides, cell cycle, immunoprecipitation, and apoptosis experiments were conducted to further explore the signaling pathways. Results: By analyzing series of 158 PTC tissues, we found that USP33 was down-regulated in tumor tissue compared with normal thyroid tissues, which was closely associated with lymph node metastasis (P<0.001). In particular, univariate and multivariate analyses indicated that USP33 was an independent prognostic biomarker for PTC, low USP33 expression indicated high recurrence risk. Cellular studies with TPC-1 and BCPAP cells demonstrated that USP33 can attenuate the cell capacities of proliferation, migration and invasion. Fluorescence-activated cell sorting experiment found no significant effect of USP33 on cell cycle, whereas the apoptotic caspase proteins were activated by USP33-overexpression. Moreover, the interaction between USP33 and Robo1 protein was identified, and knockdown of Robo1 enhancing the oncogenic effect upon USP33-knockdown, suggesting that USP33 may inhibit tumor progression through Robo1 signaling. Conclusions: Our data demonstrated that USP33 downregulation in PTC tissues was correlated with poor clinical outcome, which may serve as a novel biomarker and potential therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document